StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

N-3,4-Dimethylisoxazol-5-yl-N-sulfanilylacetamid

Sulfisoxazole Acetyl

HCID 6662
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
80-74-0
Standard-SMILES
CC(=O)N(c1onc(C)c1C)S(=O)(=O)c1ccc(N)cc1
InChIKey
JFNWFXVFBDDWCX-UHFFFAOYSA-N
Summenformel
C13H15N3O4S
Durchschnittliche Molmasse
309,34 g/mol
Monoisotopische Masse
309,07832714

Überblick

Sulfisoxazole acetyl is a member of benzenes and a sulfonamide.

Namen und Bezeichner

Bevorzugter Name
Sulfisoxazole Acetyl
IUPAC
N-(4-aminophenyl)sulfonyl-N-(3,4-dimethyl-1,2-oxazol-5-yl)acetamide
Lokaler Name
N-3,4-Dimethylisoxazol-5-yl-N-sulfanilylacetamid
Englischer Name
SULFISOXAZOLE ACETYL (200 MG)
Summenformel
C13H15N3O4S
Molmasse
309.3409

Namen und Synonyme

Sulfisoxazole acetyl80-74-0ACETYL SULFISOXAZOLELipo GantrisinacetylsulfafurazoleAcetylsulfisoxazoleGANTRISIN PEDIATRICAcetyl sulfafurazoleSulfafurazole acetylSulfisoxizole acetylWBT5QH3KEDNSC-759138
Weitere Namen anzeigen
ASIZN1-AcetylsulfisoxazoleSULFISOXAZOLE ACETYL (200 MG)Sulfisoxazole Acetyl (1639003)1-(oxazol-2-ylsulfinyl)ethanone
Sulfisoxazole acetyl (USP)Sulfisoxazole acetyl [USP]N-3,4-Dimethylisoxazol-5-yl-N-sulphanilylacetamideAcetamide, N-((4-aminophenyl)sulfonyl)-N-(3,4-dimethyl-5-isoxazolyl)-N-(4-aminobenzenesulfonyl)-N-(3,4-dimethyl-1,2-oxazol-5-yl)acetamideAcetamide, N-[(4-aminophenyl)sulfonyl]-N-(3,4-dimethyl-5-isoxazolyl)-RefChem:56070201-305-3

Datenbank-Bezeichner

CAS
80-74-0
PubChem CID
6662
DTXSID
DTXSID4023620

Eigenschaften

Berechnete Struktureigenschaften

XLogP
1,3
Polarare Oberfläche (TPSA)
115 Ų
H-Brücken-Donoren
1
H-Brücken-Akzeptoren
6
Frei drehbare Bindungen
3
Schwere Atome
21
Formalladung
0
Komplexität
482

Experimentelle und physikochemische Eigenschaften

Drugs · 2 Einträge

Pharmaceuticals -> Antibiotics

Pharmaceuticals -> Listed in ZINC15

Human Drugs · 2 Einträge

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Collision Cross Section161.2 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physikochemische Eigenschaften

Schmelzpunkt
193 · 193-194°
Siedepunkt
538.1 · 538.1±60.0 °C(Predicted)
Dichte
1.3541 · 1.3541 (rough estimate)
Brechungsindex
1.632 · 1.6320 (estimate)
pka
-0.17 · -0.17±0.10(Predicted)
Aggregatzustand
Solid
Farbe
White to off-white
Wasserlöslichkeit
80 mg/L · 80mg/L(37 ºC)

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

Sicherheitsdaten

wgk
WGK 3
hs_code
2935904000
Speicherklasse
11 - Combustible Solids

Chemie und Industrie

Pharmakologische Informationen

Protein BindingApproximately 85% of a dose of sulfisoxazole is bound to plasma proteins, primarily to albumin; 65% to 72% of the unbound portion is in the nonacetylated form.
Pharmacodynamics · 1 Eintrag

Sulfisoxazole is a sulfonamide antibiotic. The sulfonamides are synthetic bacteriostatic antibiotics with action against most gram-positive and many gram-negative organisms. Many strains of an individual species may be resistant to this drugf. Sulfonamides inhibit the multiplication of bacteria by acting as competitive inhibitors of <i>p</i>-aminobenzoic acid in the folic acid metabolism cycle. Bacterial sensitivity is the same for the various sulfonamides, and resistance to one sulfonamide indicates resistance to all. Although these drugs are no longer used to treat meningitis, CSF levels are high in meningeal infections. Their antibacterial action is inhibited by pus.

Mechanism of Action · 1 Eintrag

Sulfisoxazole is a competitive inhibitor of the enzyme dihydropteroate synthetase. It inhibits bacterial synthesis of dihydrofolic acid by preventing the condensation of the pteridine with para-aminobenzoic acid (PABA), a substrate of the enzyme dihydropteroate synthetase. The inhibited reaction is necessary in these organisms for the synthesis of folic acid.

Biological Half-LifeThe serum half-life is 10 -12 hours.
Metabolism/Metabolites · 1 Eintrag

Sulfisoxazole acetyl is a prodrug of _sulfisoxazole_. The acetyl group is added to make the drug poorly water-soluble and is hydrolyzed in vivo to the active drug,. N1-acetyl sulfisoxazole is metabolized to sulfisoxazole by digestive enzymes in the gastrointestinal tract and is absorbed as sulfisoxazole. This enzymatic splitting is thought to be responsible for slower absorption and lower peak blood concentrations are achieved after administration of an equal oral dose of sulfisoxazole. With sustained administration of acetyl sulfisoxazole, blood concentrations approximate those of sulfisoxazole. Following a single 4 gram dose of acetyl sulfisoxazole to healthy volunteers, maximum plasma concentrations of sulfisoxazole ranged from 122 to 282 mcg/mL (mean, 181 mcg/mL) for the pediatric suspension and occurred between 2 and 6 hours postadministration of sulfisoxazole, in a pharmacokinetic study.

Zugehörige Reaktionen

0
Reaktionsaufzeichnung erstellen
Noch keine zugehörigen Reaktionen

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
ChEMBL
CHEMBL1200910
ChEBI
CHEBI:135975
UNII
WBT5QH3KED
EC Number
201-305-3
Nikkaji
J4.254D
Major Application
pharmaceutical (small molecule)
InChI
1S/C13H15N3O4S/c1-8-9(2)15-20-13(8)16(10(3)17)21(18,19)12-6-4-11(14)5-7-12/h4-7H,14H2,1-3H3
InChIKey
JFNWFXVFBDDWCX-UHFFFAOYSA-N
SMILES
[S](=O)(=O)(N(c2[o]nc(c2C)C)C(=O)C)c1ccc(cc1)N
Absorption, Distribution and Excretion · 4 Einträge

Readily absorbed from the gastrointestinal tract. In a pharmacokinetic study, the adjustments for variable renal clearances between oral and intravenous administration and using the unbound plasma concentrations, the bioavailability for an oral dose of sulfisoxazole was found to be 0.95 +/- 0.04.

The mean urinary excretion recovery following oral administration of sulfisoxazole is 97% within 48 hours, of which 52% is the parent drug, and the remaining as the N4-acetylated metabolite. It is excreted in human milk. Sulfisoxazole and its acetylated metabolites are excreted primarily by the kidneys through glomerular filtration.

The sulfonamides are widely distributed throughout all body tissues. It readily crosses the placental barrier and enters into fetal circulation and also crosses the blood-brain barrier. In healthy subjects, cerebrospinal fluid concentrations of sulfisoxazole vary; in patients with meningitis, however, concentrations of free drug in cerebrospinal fluid as high as 94 mcg/mL have been reported. In a pharmacokinetic study, the apparent volume of distribution for total drug was 10.9 +/- 2.0 liters and 136 +/- 36 liters for the unbound drug, indicating that sulfisoxazole is primarily distributed extracellularly.

The clearance of sulfisoxazole is 18.7 +/- 3.9 ml/min for total drug and 232 +/- 64 ml/min for the unbound drug.

Anwendungen

VerwendenAntibacterial.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

AcetylsulfonamideIsoxazolAnhydrous pyridineEssigsäureanhydridSulfafurazol